PCSK9 and cardiovascular disorder: The proprotein convertase subtilisin/Kexin type 9 (PCSK9) has gained attention as a potential therapeutic target for lowering cholesterol levels, especially in homozygous familial hypercholesterolemia (FH)/high-risk and/or category patients who do not reach the low-density lipoprotein (LDL) target, a major risk factor for cardiovascular diseases [6,7,8].